Shows
Johnson & Johnson News DailyJohnson & Johnson Surges to Yearly High on Robust Pharma Performance# Johnson & Johnson Stock Analysis: Record Highs, Strong Performance, and Future OutlookDive into our latest podcast episode where we analyze Johnson & Johnson's impressive market performance, trading at over $204 per share—its highest level this year. Discover how this healthcare giant has achieved an 18% gain over the past year and an impressive 30% surge year-to-date, outperforming the large-cap healthcare sector.We explore the key drivers behind J&J's momentum, including successful late-stage clinical trials and remarkable growth in pharmaceutical brands like Stelara and Tremfya. Learn how the company's quarterly revenue is approaching $24 billion, demonstrating the strength of its di...
2025-11-2402 minJohnson & Johnson News DailyJohnson & Johnson Soars to New Highs, Impressing Investors Amid Robust Growth# Johnson & Johnson Stock Soars to Historic Highs: What Investors Need to Know | Investing Pulse PodcastIn this episode of Investing Pulse, we analyze Johnson & Johnson's remarkable stock performance as shares recently closed at an all-time high of $203. With a stunning 43% year-to-date appreciation and 36% growth over the past twelve months, J&J has become a standout performer in the healthcare sector.We dive into what's driving this pharmaceutical giant's success, including recent European biosimilar approvals, strong financial fundamentals with quarterly margins exceeding 27%, and revenues topping $24 billion. With a market cap approaching $489 billion, J&J maintains its position...
2025-11-2102 minJohnson & Johnson News DailyJohnson & Johnson Surges to New Highs Amid Robust Financials and Analyst Optimism# Johnson & Johnson Stock Soars to Near One-Year High: Q3 Results Drive Record Trading Volume | Investor Insights PodcastIn this episode, we dive deep into Johnson & Johnson's remarkable market performance, with shares trading at $199.71 as of November 18, 2025—approaching a one-year high. We analyze the extraordinary trading volume spike to over 13 million shares (nearly 50% above the daily average), signaling intense investor interest following the company's impressive Q3 2025 results.Discover how J&J achieved a stunning 7% sales growth to $24 billion and a remarkable 90% increase in net earnings despite Stelara patent challenges. We explore the strategic $3.1 billion Halda acquisition strengthening J...
2025-11-1902 minJohnson & Johnson News DailyJohnson and Johnson Surges on Halda Acquisition and Robust Financials# Johnson & Johnson Stock Soars After $3B Halda Therapeutics Acquisition | Healthcare Investment AnalysisDiscover why Johnson & Johnson (JNJ) stock jumped 1.74% to $199.34 with heightened trading volume following its strategic $3 billion acquisition of Halda Therapeutics. In this episode, we analyze how this major move strengthens J&J's oncology portfolio and cancer drug development pipeline. We break down J&J's impressive 4.3% revenue growth to $88.82 billion for 2024, explore why Scotiabank names it a top pick for curative treatments, and examine analyst projections suggesting a potential 4.47% upside to $207.65. Learn why JNJ has gained over 35% year-to-date and why it remains an attractive healthcare sector investment...
2025-11-1801 minJohnson & Johnson News DailyJohnson & Johnson Poised for Steady Growth Amid Legal Risks and Competitive Challenges# J&J Stock Analysis: Strong Performance and Growth Potential in Healthcare GiantExplore Johnson & Johnson's impressive stock performance in our latest podcast episode. Trading near $196 with a market cap exceeding $470 billion, J&J remains a healthcare powerhouse. We analyze the stock's 30%+ year-to-date growth and 5% weekly gains that have investors taking notice.Discover why analysts maintain a "moderate buy" consensus with price targets ranging from $200-$225, reflecting confidence in J&J's pharmaceutical division and promising oncology pipeline. Learn about the company's recent quarterly surprise with nearly 6% adjusted operational sales growth and how its oncology portfolio could drive $50...
2025-11-1702 minJohnson & Johnson News DailyJ&J's Resilient Growth Marks Steady Upward Momentum# Johnson & Johnson (JNJ) Stock Rises on Strong Q3 Performance and Upbeat OutlookIn this insightful podcast episode, we analyze Johnson & Johnson's current market position as its stock trades at approximately $194 per share, showing steady momentum with a modest 1% gain in recent trading. We dive deep into JNJ's impressive Q3 results, where the healthcare giant exceeded expectations with $2.80 earnings per share and nearly 7% organic sales growth, leading management to raise their 2025 revenue guidance.The episode explores how standout performers like Darzalex and Tremfya are successfully offsetting revenue challenges from Stelara's patent expiration, while the MedTech segment continues...
2025-11-1402 minJohnson & Johnson News DailyJohnson & Johnson Soars to New Highs, Riding Investor Optimism and Diversified Growth# Johnson & Johnson Stock Soars to Historic Highs: Investor Confidence Fuels 30% YTD SurgeIn this episode, we analyze Johnson & Johnson's remarkable market performance as the healthcare giant's stock trades near an all-time high of $194.50. Discover why trading volumes have consistently exceeded 5 million shares daily, signaling heightened investor interest in this pharmaceutical powerhouse. We examine J&J's impressive momentum metrics, including a 7% gain over the past month, 18% growth over the last year, and an exceptional 30% year-to-date increase—outstanding performance for a company approaching $460 billion in market cap.Learn about recent institutional confidence signals, including Cadinha & Company's significant $15.7 million in...
2025-11-1302 minJohnson & Johnson News DailyJohnson & Johnson Navigates Volatility and Legal Risks Amid Solid Fundamentals# Johnson & Johnson Stock Analysis: Healthcare Giant's Latest Performance and Investment OutlookDive into our detailed breakdown of Johnson & Johnson's current market position as one of healthcare's most influential players. Trading near $186, J&J recently experienced a slight pullback despite beating quarterly earnings estimates with impressive 15% growth. We examine the stock's performance range ($141-$194), analyze above-average trading volumes suggesting heightened investor interest, and explore why analysts maintain overwhelmingly positive ratings with a consensus target of $199.This episode covers J&J's attractive 2.7% dividend yield for income investors, its strategic pivot toward high-growth healthcare segments, and potential market catalysts...
2025-11-0502 minJohnson & Johnson News DailyJohnson & Johnson's Steady Performance Amid Sector Challenges# Johnson & Johnson's Strategic Pivot: Healthcare Giant Plans Orthopedics Spinoff as Stock Shows ResilienceIn this insightful podcast episode, we analyze Johnson & Johnson's current market position and strategic transformation. Trading near $189, this healthcare behemoth recently surprised investors with impressive Q3 earnings growth of 15.7% and an upgraded sales forecast. We dive deep into J&J's planned orthopedics division spinoff and how this strategic streamlining aims to fuel future growth.With a market cap approaching $450 billion and analyst price targets reaching as high as $209, what does the future hold for this dividend stalwart yielding 2.8%? Listen as we examine the...
2025-11-0402 minJohnson & Johnson News DailyJohnson & Johnson's Steady Climb Amid Healthcare Sector Strength# Johnson & Johnson Stock Analysis: Outperforming the Market in 2025In this insightful episode, we dive deep into Johnson & Johnson's impressive market performance as of early November 2025. Trading around $188 per share, J&J has delivered stellar 30% year-to-date gains, significantly outpacing the S&P 500's 16% growth. We analyze the company's recent quarterly results showing 7% revenue growth to $24 billion and a 16% increase in adjusted EPS to $2.80, which prompted management to raise its full-year revenue forecast to approximately $93.2 billion.Our expert discussion covers the strong analyst sentiment surrounding J&J, with most rating it a "moderate buy" and price targets reaching...
2025-11-0302 minJohnson & Johnson News DailySteady Performance, Strong Earnings, and Positive Outlook for Johnson & Johnson# Johnson & Johnson Stock Analysis: Strategic Moves and Positive OutlookIn this episode, we dive into Johnson & Johnson's current market performance, with the healthcare giant trading at $189.05 per share. Despite lower-than-average trading volume of approximately 7 million shares, J&J shows remarkable stability and steady growth trajectory.We explore J&J's impressive quarterly earnings report, highlighting a substantial 15.7% increase in adjusted earnings per share year-over-year. The company's decision to spin off its orthopedics division into a separate publicly traded entity represents a strategic refocusing that could potentially unlock significant shareholder value.Our analysis covers the overwhelmingly...
2025-10-3101 minJohnson & Johnson News DailyJohnson & Johnson Stock Holds Steady Amid Sector Shifts# Johnson & Johnson Stock Analysis: Market Position, Analyst Ratings & Future OutlookDiscover the latest updates on Johnson & Johnson (JNJ) in this comprehensive market analysis episode. We examine JNJ's current trading position at $190.40, representing a slight decline despite broader market gains, and analyze what reduced trading volume (6.9M vs 8.9M 30-day average) signals to investors. Learn how recent developments, including promising phase two nipocalimab study results for Sjogren's disease, are impacting this pharmaceutical giant's $459B market capitalization. We break down Wall Street's moderate buy consensus, featuring insights from 26 analysts and price targets ranging from $170 to $225, with an average...
2025-10-2702 min
Progress, Potential, and Possibilities Podcast / ShowJoel Krikston - Managing Director Venture Investments, Merck Global Health Innovation Fund / Co-Founder, MSD Idea Studios - Investments To Improve Patients' LivesSend us a textJoel Krikston is a seasoned executive with extensive experience in venture investments and strategic innovation within the healthcare sector.Joel currently serves as Managing Director Venture Investments Merck Global Health Innovation Fund ( https://www.merckghifund.com/?profile=joel-krikston ) and Co-Founder of MSD Idea Studios ( https://www.msd.de/ideastudio/ ), a global innovation hub organization that is committing $38 million to scale high-impact health technologies that directly align with Merck’s access and R&D priorities. They are strategically located in the innovation hubs of Singapore and Berlin. With a career spa...
2025-10-2357 minJohnson & Johnson News DailyJohnson & Johnson Delivers Resilience in Volatile Market# SEO-Friendly Podcast Episode Description**Johnson & Johnson Stock Analysis: Market Position, Investor Sentiment, and Future Outlook**In this insightful podcast episode, we dive deep into Johnson & Johnson's current market performance, analyzing its $191.88 closing price on October 21, 2025, and recent trading patterns. Discover why this healthcare giant maintains its impressive $467 billion market capitalization and what its trading volume indicates about investor confidence.We explore J&J's appeal as a defensive healthcare investment during market uncertainty, examining how its diversified business model across pharmaceuticals, medical technology, and consumer health products creates unmatched stability. Learn about the attractive 3% dividend...
2025-10-2202 minJohnson & Johnson News Daily"Johnson & Johnson Navigates Challenges, Maintains Investor Confidence in Volatile Market"# Johnson & Johnson Stock Analysis: Resilience Amid Market Challenges | Finance Market UpdateDive into our latest podcast episode examining Johnson & Johnson's current market position as it trades at $144 USD on October 20, 2025. We break down J&J's recent quarterly performance, which exceeded earnings expectations despite moderate revenue growth. Discover how the company's MedTech division—particularly surgical technology and orthopedics—continues driving growth after the consumer health division spinoff.Our analysis covers Wall Street's bullish outlook, with major banks raising price targets to $150 and maintaining overweight ratings based on J&J's defensive qualities during market volatility. We examine how the...
2025-10-2001 min
Sobering Stories PodcastDoes TYLENOL Really CAUSE AUTISM???💊 If you can’t tough it out, then you can support the sponsor,but otherwise do not support the sponsor ❤️🚨 Tylenol's Coal-Tar Secret 🤫#TylenolAutism #JandJScandals #BigPharmaExposed #SoberingStoriesEver pop that red bottle thinking it's grandma's gentle fix? Turns out, it's born from 19th-century war sludge—Big Pharma's idea of a plot twist. In this Sobering Stories dig, we unearth acetaminophen's buried lab flubs (1878 to Elixir boom), the 2025 prenatal autism buzz (20-30% higher odds?), and J&J's slide from bandage saints to poison peddlers: Cyanide dumps, talc ghosts, and a rogue's gallery of faults that scream deflection. Is it real risk... or cabal smoke fo...
2025-10-171h 13Johnson & Johnson News DailyJ&J Shines with Oncology Breakthroughs and Analyst Confidence Amid Resilient Growth# Johnson & Johnson Stock Analysis: Positive Clinical Trials Boost Investor ConfidenceIn this insightful episode, we analyze Johnson & Johnson's current market position as shares approach their 52-week high of $194.40, significantly above the year's low of $140.68. We explore the breakthrough Phase Three MajesTEC-3 trial results for Tecvayli, which demonstrated superior outcomes for multiple myeloma patients when combined with Darzalex Faspro. Learn why major investment firms like Goldman Sachs and Citigroup have raised their price targets above $212, contributing to the consensus "moderate buy" rating.Our experts break down J&J's impressive fundamentals, including its $460+ billion market cap, P/E...
2025-10-1702 minJohnson & Johnson News DailyPowering Ahead: Johnson & Johnson's Impressive Q3 and Promising Outlook# Johnson & Johnson Stock Soars on Impressive Q3 Results: Financial Analysis & Market OutlookDive into our latest podcast episode exploring Johnson & Johnson's remarkable market performance, with shares trading near $191 following exceptional Q3 results. We analyze the significant 7% sales growth reaching $24 billion, the stunning 91% increase in net earnings, and what drove trading volume to surge past 13 million shares—well above the typical 8.7 million daily average.Discover why analysts are upgrading their outlook, with Guggenheim elevating JNJ to a "Buy" rating and TD Cowen raising their price target to an impressive $222. We examine how JNJ's strong performance in both In...
2025-10-1502 minJohnson & Johnson News DailyJohnson & Johnson Stock: Balancing Cautious Optimism and Operational Risks# Johnson & Johnson Stock Analysis: Trading Near 12-Month High with Cautious Analyst OutlookExplore our latest podcast episode dissecting Johnson & Johnson's current market position, with shares trading around $190.72 – near its 12-month high of $192.10 and significantly above January's low of $140.68. We analyze the below-average trading volume suggesting consolidation after recent gains, and examine diverse analyst perspectives ranging from Barclays' equal weight rating to UBS's bullish stance.Discover how JNJ's Innovative Medicine division, powered by blockbusters Darzalex and Tremfya, drives growth alongside new product launches that maintain revenue momentum despite patent expirations. We evaluate how the company's strong cash fl...
2025-10-1302 minJohnson & Johnson News DailyJohnson & Johnson Steady Performance and Growth Outlook# Johnson & Johnson Stock Analysis: Steady Growth and Strong Financial PerformanceIn this episode, we dive deep into Johnson & Johnson's current market position, with shares trading around $191 USD and showing remarkable stability near its 52-week high. We analyze the company's impressive quarterly earnings that exceeded expectations, with EPS of $2.77 and annual revenue growth of nearly 6% to over $23 billion.Discover why major financial institutions like Bank of America and RBC Capital are upgrading their price targets for J&J stock, with analysts highlighting strong performance in the Innovative Medicine and MedTech divisions. Learn about the consensus "moderate buy"...
2025-10-1002 minJohnson & Johnson News DailyJohnson & Johnson's Resilience Amid Market Uncertainties: A Closer Look# Johnson & Johnson Stock Reaches New Heights: Financial Analysis & Outlook for InvestorsDiscover the latest financial performance of Johnson & Johnson (JNJ) as the healthcare giant continues its impressive market run. This episode breaks down JNJ's recent stock movements, trading patterns, and analyst projections that matter to investors.We analyze JNJ's October 9th price action, where the stock opened at $189.75 with a 0.5% gain, approaching its 52-week high of $190.22. With a market cap of $456.98 billion and solid financial metrics, including a P/E ratio of 20.29 and a conservative debt-to-equity ratio of 0.50, Johnson & Johnson maintains its position as a healthcare...
2025-10-0902 minJohnson & Johnson News DailyJohnson & Johnson's Resilient Growth Prospects Attract Investors in Volatile Market# Johnson & Johnson Stock Analysis: Strong Performance & Growth Outlook | Investing PodcastExplore Johnson & Johnson's impressive market performance as the stock approaches its one-year high of $189.78. In this episode, we analyze JNJ's remarkable 31% year-to-date growth and 22% annual gain, backed by solid trading volumes showing investor confidence rather than speculation.Dive into JNJ's robust financial health, including its $454 billion market cap, healthy P/E ratio around 20, and recent quarterly earnings that exceeded expectations at $2.77 per share. Learn how the company's nearly $24 billion in revenue represents a strong 6% year-over-year increase, with projected full-year EPS between $10.80-$10.90.We cover...
2025-10-0602 minJohnson & Johnson News DailyNavigating Johnson & Johnson's Record Highs: Insights into the Healthcare Giant's Momentum# Johnson & Johnson Stock Analysis: Trading Near Record Highs as Healthcare Leader Outperforms MarketExplore the remarkable performance of Johnson & Johnson (JNJ) in our latest podcast episode, where we analyze how this healthcare giant has reached near-record highs of $186.05 (as of October 1), delivering an impressive 24%+ gain year-to-date while outperforming the broader healthcare sector. We dive into the significant trading volume spike to 13 million shares—well above its 9 million average—signaling heightened investor interest in this market leader.Discover the solid fundamentals driving JNJ's momentum, including their exceptional Q3 earnings report featuring $2.77 EPS (beating expectations by $0.09) and nearly 6% reve...
2025-10-0302 minJohnson & Johnson News DailyJohnson & Johnson Surges Amid Analyst Upgrades and Robust Earnings# Johnson & Johnson Surges: Stock Analysis and Bullish Analyst Outlook | Investing PodcastIn this informative episode, we dive deep into Johnson & Johnson's recent market performance as the healthcare giant's stock climbs to $185.40, representing a notable 2% gain in the latest trading session. We explore how J&J is currently trading near the upper end of its 52-week range ($128-$161), with trading volume surging 35% above daily averages to over 11 million shares.Our financial experts analyze the company's impressive $446 billion market capitalization and P/E ratio of 19.83, indicating its premium valuation compared to industry peers. We break down recent analyst...
2025-10-0102 minProgress, Potential, and Possibilities Podcast / ShowDr. Mark Lloyd Davies - Global Head, Strategic Partnerships and Resource Group, Johnson & Johnson - Strategic Public-Private Partnerships To Transform LivesSend us a textDr. Mark Lloyd Davies, Ph.D. is the Global Head for the Strategic Partnerships and Resource Group at Johnson & Johnson ( https://www.jnj.com/ ) where he leads a global team that forges novel strategic public-private partnerships to secure collaborations that accelerate groundbreaking R&D, advances strategies that widen access to care for patients and health systems worldwide, and ultimately unlocks possibilities that transform lives.Dr. Davies has built a distinguished career at the intersection of science, policy, and global health strategy.Before taking on his current global role, Dr...
2025-09-3039 minJohnson & Johnson News DailyJohnson & Johnson: Healthcare Powerhouse Consolidating Its Blue-Chip Status# Johnson & Johnson's Market Dominance: Financial Growth, Analyst Confidence, and Investment OutlookIn this revealing episode, we dive deep into Johnson & Johnson's impressive market performance as one of healthcare's top-performing large-cap companies. Discover how J&J reached new highs with a closing price of $181.62 and why analysts are projecting targets up to $200, reflecting growing confidence in the company's sector leadership.We analyze J&J's exceptional financial strength with $90+ billion in revenue and $22 billion in net income, plus their recent earnings beat of $2.77 per share on $23+ billion quarterly revenue. Learn why management's full-year EPS guidance of $10.80-$10.90 signals...
2025-09-3002 min
Ian & Rashad Present Black Out Unfiltered UncutTrump, Tylenol & Autism: Breaking Down the ControversyIn this thought-provoking clip from "Black Out with Ian & Rashad," your favorite hosts dive deep into the recent controversy sparked by Donald Trump’s administration warning about the use of Tylenol during pregnancy and its alleged link to autism. Rashad and Ian unpack what was actually said, the internet’s explosive reaction, and the complexities surrounding medical advice when it comes to pregnancy.Rashad starts by quoting Trump’s claim and discusses the subsequent FDA response, including potential warnings for pregnant women and whether there were already existing cautions or risks previously noted. Ian chimes...
2025-09-2708 minJohnson & Johnson News DailyJohnson & Johnson Holds Steady Amid Talc Litigation and Pricing Pressures# Johnson & Johnson Stock Update: Steady Performance Amid Market FluctuationsDiscover the latest financial insights on Johnson & Johnson (JNJ) as the healthcare giant maintains steady performance at $178 per share. This episode breaks down J&J's impressive 23% year-to-date growth and recent quarterly results showing $21B in revenue with 2.4% year-over-year growth. Learn how the company's pharmaceutical and medtech segments—particularly the innovative Ottava robotic surgery platform—are driving consistent performance despite market volatility.We analyze analyst sentiment, valuation metrics, and why J&J trades at a P/E ratio of 19 (below market averages), potentially representing a defensive opportunity in toda...
2025-09-2602 minJohnson & Johnson News DailyJohnson & Johnson Steady as She Goes - A Stable Outlook for the Healthcare Giant# JNJ Stock Update: Johnson & Johnson Demonstrates Steady Performance Amid Analyst OptimismExplore Johnson & Johnson's latest market performance as the healthcare giant closed at $177.20 on September 17, 2025. This episode analyzes JNJ's trading patterns, highlighting moderate trading volumes of 6.6 million shares—slightly below the recent daily average. Discover how Morgan Stanley's revised price target to $176 and a consensus "moderate buy" rating from 21 Wall Street analysts are shaping investor sentiment.We break down JNJ's impressive Q2 earnings report that exceeded expectations with $2.77 EPS and examine the company's healthy 25% profit margins. Learn why institutional investors maintain strong confidence in this blue-chip st...
2025-09-1802 minJohnson & Johnson News DailyJohnson & Johnson's Steady Climb: Navigating Investor Sentiment and Positive Outlook# Johnson & Johnson Stock Analysis: Financial Strength, Analyst Perspectives, and Future Outlook | Market Watch PodcastIn this insightful episode, we dive deep into Johnson & Johnson's current market position, trading at approximately $176.50 per share—just shy of its yearly high but significantly above its annual low. We examine the recent surge in trading volume to nearly 8 million shares, exceeding the daily average of 7 million, and what this increased investor activity might signal.Our experts analyze J&J's impressive financial fundamentals, including its $425 billion market cap and robust Q2 performance that surpassed expectations with $2.77 earnings per share and 6% year-over-year re...
2025-09-1702 min
Toxic Exposures, Cancer Lawsuits & Justice: Mesothelioma, Defective Drugs, Radiation Injuries, Environmental Contamination & Legal Settlements Explained.Talcum Powder Ovarian Cancer Lawsuits | Johnson & Johnson Baby Powder Cancer Risks, Asbestos Exposure, Legal Settlements, Compensation Claims & Justice for Women Worldwide.This episode uncovers the truth about talcum powder ovarian cancer lawsuits, focusing on Johnson & Johnson’s baby powder and its hidden asbestos contamination. For decades, women trusted talcum powder as a safe product, only to discover its direct link to ovarian cancer. Billions of dollars in settlements have already been awarded, yet thousands of cases are still pending in courts across the U.S. and UK. Learn how medical studies exposed corporate negligence, why regulators failed to protect consumers, and what victims can do today to claim justice. We break down step-by-step how lawsuits work, what evidence is required, an...
2025-09-1401 min
Toxic Exposures, Cancer Lawsuits & Justice: Mesothelioma, Defective Drugs, Radiation Injuries, Environmental Contamination & Legal Settlements Explained.Talcum Powder Ovarian Cancer Lawsuit | Johnson & Johnson Baby Powder Claims, Women’s Health Justice & Billion-Dollar Settlements.In this episode, we uncover the truth behind the talcum powder ovarian cancer lawsuits that shook the corporate world. For decades, Johnson & Johnson’s baby powder was marketed as safe for daily use. Later, medical studies revealed a possible link between talc products and ovarian cancer in women. Thousands of victims have filed lawsuits, and courts have already awarded multi-billion-dollar settlements. We’ll explain the science, legal claims, and how you may still qualify to join ongoing litigation.#TalcumPowderLawsuit #OvarianCancerClaims #JohnsonAndJohnson #WomensHealthJustice #HighCompensation #LegalAwareness #DefectiveProduct
2025-09-1401 min
Toxic Exposures, Cancer Lawsuits & Justice: Mesothelioma, Defective Drugs, Radiation Injuries, Environmental Contamination & Legal Settlements Explained.Talcum Powder Ovarian Cancer Lawsuits: Johnson & Johnson, Asbestos Contamination, Women’s Health Crisis, Corporate Negligence & Multi-Billion Dollar Settlements.For decades, women trusted talcum powder for hygiene. But hidden inside was asbestos contamination, linked to ovarian cancer and mesothelioma. Thousands of women filed lawsuits exposing corporate negligence and failure to warn consumers. Courts have already ordered multi-billion dollar settlements against Johnson & Johnson.This episode uncovers the truth behind the talcum powder lawsuits, women’s health battles, and the pursuit of justice.#TalcumPowderLawsuits #OvarianCancerAwareness #JohnsonAndJohnson #AsbestosContamination #CorporateNegligence #MultiBillionDollarSettlements #WomenHealthJustice #HighRPMPodcast
2025-09-1201 min
Toxic Exposures, Cancer Lawsuits & Justice: Mesothelioma, Defective Drugs, Radiation Injuries, Environmental Contamination & Legal Settlements Explained.Risperdal Gynecomastia Lawsuits: Dangerous Antipsychotic Drug, Male Breast Growth, Johnson & Johnson Negligence & Billion-Dollar Settlements.Risperdal, an antipsychotic drug, was prescribed to children and young men. But many developed gynecomastia – abnormal male breast growth, causing trauma and permanent physical changes. Lawsuits against Johnson & Johnson have led to multi-billion dollar verdicts.This episode uncovers the truth about Risperdal lawsuits, corporate negligence, and justice for victims.#RisperdalLawsuits #GynecomastiaAwareness #DrugSideEffects #JohnsonAndJohnson #CorporateNegligence #LegalCompensation #HighRPMPodcast #MultiBillionDollarSettlements
2025-09-1200 minJohnson & Johnson News DailyJohnson & Johnson Stock Outlook: Stable but Limited Upside in Uncertain Environment# Johnson & Johnson Stock Analysis: Navigating Legal Challenges Amid Steady PerformanceIn this episode, we dive deep into Johnson & Johnson's current market position, where shares recently closed near $178, showing resilience despite significant headwinds. We explore the stock's unusual trading patterns, including an 85% volume drop followed by $1 billion in activity, and what this volatility signals for investors.Our analysis unpacks the consensus "moderate buy" rating from 20 analysts and examines recent target price increases from major firms like Bank of America and Morgan Stanley. We break down how ongoing legal battles over opioid distribution and FDA delays for oncology...
2025-09-1202 minJohnson & Johnson News DailyJohnson & Johnson Soars on Approval of Bladder Cancer Device, Solid Earnings# Johnson & Johnson Stock Analysis: New Cancer Treatment Approval Boosts Growth OutlookIn this insightful episode, we dive deep into Johnson & Johnson's current market position, trading at approximately $177 per share after a slight dip from $178. Despite three consecutive down days, the healthcare giant remains near its 12-month high with unusually light trading volume—just 1.2 million shares compared to the typical 9 million average.Discover how J&J's impressive 15% three-month price climb outperforms the broader market, and learn about the game-changing FDA approval of Inlexzo, their innovative bladder cancer treatment device. We explore management's bullish forecast of $5+ billion in an...
2025-09-1002 minJohnson & Johnson News Daily"Johnson & Johnson's Resilience: Navigating Legal Hurdles and Sustaining Growth"# Johnson & Johnson Stock Analysis: Steady Growth Amid Legal Resolutions | Investment Market UpdateExplore the latest Johnson & Johnson (JNJ) stock performance in our comprehensive market analysis podcast. We break down JNJ's current trading position at $178.76, representing a steady upward trend with impressive late-summer momentum. Learn why analyst ratings remain cautiously optimistic with 12-month targets ranging from $176-195, and discover the significance behind JNJ's attractive P/E ratio of 19 paired with its reliable 3%+ dividend yield that continues attracting institutional investors.This episode examines JNJ's impressive quarterly results showing 6% year-over-year sales growth and their raised full-year outlook following the...
2025-09-0502 min
Stuttering in SilenceThe Capsule Killer: The Tylenol Murders of 1982In this chilling episode of Stuttering in Silence, Matt and Gavin take us back to Chicago in 1982 — when ordinary bottles of Tylenol turned into weapons of mass fear. Seven people died in just days, and America’s most trusted pain reliever suddenly became the face of terror.Together, the hosts unpack how Johnson & Johnson went from “America’s family company” to the center of a national panic, the shocking recall that rewrote corporate crisis management forever, and the haunting theories about who really laced those capsules with cyanide. From the bearded man caught on tape, to James Lewis’s ex...
2025-09-041h 02Johnson & Johnson News DailyJohnson & Johnson: A Healthcare Stalwart Blending Innovation and Stability# Johnson & Johnson Stock Analysis: Healthcare Giant Trading Near 52-Week HighDiscover the latest financial insights on Johnson & Johnson (JNJ) in our new podcast episode. We analyze how this healthcare leader is trading just below its 52-week high of $181, with shares currently around $177, well above its yearly low of $141. Learn why JNJ continues to impress investors with exceptional quarterly earnings that exceeded expectations, posting $2.77 EPS and $23.7 billion in revenue—nearly $1 billion above analyst projections.Our episode breaks down how JNJ's innovative medicine and MedTech divisions are driving growth, management's optimistic full-year guidance of $10.80-10.90 EPS, and the st...
2025-09-0302 minJohnson & Johnson News DailySteady Upward Trend for Johnson & Johnson as Healthcare Giant Maintains Stability and Investor Confidence# Johnson & Johnson Stock Analysis: Stability, Dividends, and Future Growth OutlookExplore the latest insights on Johnson & Johnson (JNJ) stock performance in our comprehensive market analysis episode. We examine how JNJ opened at approximately $177 per share, maintaining its projected price range while trading at below-average volume. Learn why this healthcare giant, with its impressive $426+ billion market cap, continues to attract income-seeking investors through 47 consecutive quarters of dividend payments and a yield exceeding 3%.Our podcast breaks down JNJ's recent financial success, including quarterly revenues surpassing $23 billion and earnings that exceeded market expectations. We analyze the latest analyst recommendations...
2025-09-0202 min